94 filings
Page 3 of 5
8-K
lmmk7i2 dmwtlk52tpf
6 Mar 19
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
qcw09wa
6 Feb 19
Royalty revenue for the quarter increased to $69.9 million
4:05pm
8-K
9ucp33 66c
26 Nov 18
Royalty revenue for the quarter increased to $67.2 million
4:07pm
8-K
tgx6iwxd
7 Aug 18
Results of Operations and Financial Condition
12:00am
8-K
eq76g7yivo366vqrv8vp
8 May 18
Royalty revenue for the quarter increased to $44.0 million due to increase in AbbVie’s MAVYRET™ sales
4:05pm
8-K
ajsn24v 7bdjp09sl
2 Mar 18
Submission of Matters to a Vote of Security Holders
12:00am
8-K
0fq9g6pkm7mjlxwcdkn
7 Feb 18
Total revenue for the quarter was $38.1 million
12:00am
8-K
aadpjafw
20 Nov 17
Total revenue for the quarter was $75.9 million
12:00am
8-K
x2im128eo6sgm
13 Sep 17
Departure of Directors or Certain Officers
12:00am
8-K
smsv01ktp
7 Aug 17
Royalty revenue for the quarter was $7.5 million
12:00am
8-K/A
6e6o2lbqcq ocuod5yc
9 May 17
Results of Operations and Financial Condition
12:00am
8-K
t7x39
8 May 17
R&D expense increased to $13.0 million in support of pipeline development
12:00am
8-K
yv7fu5x b0g6senag
21 Feb 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
c0ztetgf
8 Feb 17
Results of Operations and Financial Condition
12:00am
8-K
dkx80qlf
6 Jan 17
Regulation FD Disclosure
12:00am
8-K
td5du6a j1q
22 Nov 16
Departure of Directors or Certain Officers
12:00am
8-K
2las5hlbtrlsilxh
21 Nov 16
Enanta Pharmaceuticals Reports Financial Results for its
12:00am
8-K
fp48467rgzn5yowbx2s2
8 Aug 16
Enanta Pharmaceuticals Reports Financial Results for its
12:00am
8-K
sbu8b
9 May 16
Enanta Pharmaceuticals Reports Financial Results for its
12:00am
8-K
zwytfjl
16 Feb 16
Submission of Matters to a Vote of Security Holders
12:00am